Form D · Biotechnology

Allyx Therapeutics, Inc.

New Haven, CT · CIK 0001865257

Offering snapshot reported Oct 21, 2026 · SEC filing

Reported sold
$27.9M
Offering amount: $30M
Investors reported
33
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 4, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$14M$27.9MMay 11, 2026: $26,427,730.00May 11, 2026Oct 21, 2026: $27,927,729.00Oct 21, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$26,427,730 → $27,927,729
  • Reported investors32 → 33

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 21, 2026Amendment$27,927,729$1,499,999vs May 11, 202633SEC filing
May 11, 2026Initial$26,427,730No comparison32SEC filing
Mar 3, 2026Initial$3,324,918No comparison12SEC filing
Feb 10, 2023Initial$2,308,569No comparison11SEC filing
Jun 2, 2021Initial$7,581,493No comparison10SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$329K
Form D file number
021-583522

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Supervision Partners LLC300528

Source: Form D, filed Oct 21, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert A Bettigole Director
Stephen Bloch Director, Executive
Paul Fonteyne Director
Jennifer Gabler Executive
Gregory P Ho Director
Kevin L. Rakin Director
Timothy Siegert Executive
Stephen Strittmatter Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
555 Long Wharf Drive Floor 11
New Haven, CT, 06511
Phone: (908) 432-2845